GlassScriptPhysician profile
Kristen Begley
NPI 1861014508
$1,805.87
in general payments reported to CMS, 2019-2025
18 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $516 · 2023: $335 · 2024: $383 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $441.31 | 2021-2024 | Farxiga |
| Boston Scientific Corporation | $282.58 | 2022-2024 | Watchman Flx, Watchman Access System |
| Abbott Laboratories | $215.71 | 2022-2024 | Jot Dx, Cardiomems |
| Inspire Medical Systems, INC. | $150.00 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $107.05 | 2023-2024 | |
| Amgen INC. | $105.41 | 2023 | Repatha |
| Edwards Lifesciences Corporation | $86.96 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amarin Pharma, INC. | $82.27 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $52.18 | 2022-2024 | Camzyos |
| Pfizer INC. | $49.60 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $46.56 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $37.46 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.85 | 2024 | Jardiance |
| Lilly USA, LLC | $27.97 | 2025 | Zepbound |
| Kowa Pharmaceuticals America, INC. | $27.56 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $23.34 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $22.64 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $18.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Begley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.